Atea Pharmaceuticals, Inc. cash flow statement

In fiscal 2021, Atea Pharmaceuticals, Inc.'s operations generated −$87.0m of cash; it spent $4,000 on capital projects, leaving free cash flow of −$87.0m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Atea Pharmaceuticals, Inc.: cash flow statement, annual
Fiscal year	2020Dec 2020	2021Dec 2021
Cash from operations	297	−87
Depreciation and amortisation	0	0
Stock-based pay	7	40
Capital spending	0	0
Free cash flow	297	−87
Free cash flow after stock pay	289	−127
Shares issued	0	1

US$ millions unless shown otherwise. Fiscal quarters.

Atea Pharmaceuticals, Inc.: cash flow statement, quarterly
Quarter	2021 Q1Mar 2021	2021 Q2Jun 2021	2021 Q3Sept 2021	2021 Q4Dec 2021
Cash from operations	−17	−17	23	−75
Depreciation and amortisation	0	0	0	0
Stock-based pay	7	10	11	11

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Atea Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Atea Pharmaceuticals, Inc.